Novartis's Piqray Gets Europe Green Light At Last
First-In-Class PI3K inhibitor Approved For Breast Cancer
Executive Summary
It has taken a while but European regulators have finally followed their US counterparts and approved Piqray, making it the first targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation.
You may also be interested in...
EU Indication Restricted For Novartis's Newly Approved Piqray
Piqray is now approved for use in almost 50 countries but not only did the novel drug from Novartis for advanced breast cancer take longer to be approved in the EU than in the US, its indication is narrower in the EU. This is the first of two articles based on the European public assessment report for the PIK3 inhibitor.
Novartis, D&A Pharma Prepare For High-Stake EMA Meetings
Oral explanation meetings are due to take place this week for drug sponsors who have a final chance to address questions and concerns the European Medicines Agency has about their marketing applications.
Novartis' New Oncology CEO Schaffert Has A Potential Blockbuster Launch On Her Hands
In an interview at Novartis' research campus in Cambridge, Mass., Schaffert spoke about the upcoming launch of Piqray for breast cancer, building in radiopharmaceuticals, Kymriah's ongoing manufacturing challenges and more.